X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
alendronic acid (513) 513
bisphosphonates (471) 471
osteoporosis (331) 331
index medicus (301) 301
humans (220) 220
alendronate (212) 212
female (198) 198
fractures (159) 159
medicine & public health (136) 136
bone (126) 126
endocrinology & metabolism (119) 119
bone mineral density (111) 111
animals (110) 110
orthopedics (104) 104
aged (103) 103
bone density conservation agents - therapeutic use (98) 98
zoledronic acid (96) 96
biocompatibility (94) 94
postmenopausal women (93) 93
male (92) 92
alendronate - therapeutic use (91) 91
middle aged (88) 88
rheumatology (84) 84
patients (83) 83
alendronate - pharmacology (82) 82
bones (78) 78
endocrinology (77) 77
risedronic acid (76) 76
bone density (75) 75
femur (74) 74
osteoporosis - drug therapy (72) 72
post-menopause (72) 72
risk factors (72) 72
hip (71) 71
women (70) 70
drug therapy (69) 69
analysis (68) 68
research (67) 67
bone resorption (66) 66
drugs (66) 66
osteoporosis, postmenopausal - drug therapy (64) 64
bone turnover (63) 63
parathyroid hormone (62) 62
pharmacology & pharmacy (62) 62
biomedical materials (61) 61
bone density - drug effects (61) 61
spine (61) 61
vertebrae (59) 59
alendronate - administration & dosage (58) 58
bone density conservation agents - administration & dosage (58) 58
postmenopausal osteoporosis (58) 58
prevention (58) 58
rats (57) 57
bone-mineral density (56) 56
diphosphonates - therapeutic use (56) 56
risk (56) 56
bone growth (55) 55
osteogenesis (55) 55
osteonecrosis (53) 53
therapy (53) 53
calcium (52) 52
care and treatment (52) 52
ovariectomy (51) 51
bisphosphonate (50) 50
bone density conservation agents - pharmacology (50) 50
clinical trials (50) 50
health aspects (49) 49
hormone replacement therapy (49) 49
aged, 80 and over (48) 48
density (47) 47
dentistry (47) 47
menopause (47) 47
bone density conservation agents - adverse effects (46) 46
pharmacology/toxicology (46) 46
multidisciplinary sciences (45) 45
studies (45) 45
in-vitro (44) 44
jaw (43) 43
rodents (43) 43
alendronic-acid, adverse reactions (42) 42
medicine (42) 42
bone loss (41) 41
sodium (41) 41
computed tomography (40) 40
phosphonates (40) 40
research article (40) 40
surgery (40) 40
vitamin d (40) 40
cancer (39) 39
bone mass (38) 38
osteoclasts (38) 38
raloxifene (38) 38
science (38) 38
alendronate - adverse effects (37) 37
collagen (37) 37
dosage and administration (37) 37
health risk assessment (37) 37
mice (37) 37
complications and side effects (36) 36
dentistry, oral surgery & medicine (36) 36
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, ISSN 0942-2056, 07/2019, pp. 1 - 10
The purpose of this study was to determine the efficacy and tolerability of different antiresorptive therapeutic regimens for treating symptomatic bone marrow... 
Knee | Evaluation | Nuclear magnetic resonance--NMR | Procollagen | Laboratories | Crosslinking | Ibandronic acid | Knee (anatomy) | Bone turnover | Patients | Alendronic acid | Pain | Acids | Magnetic resonance imaging | Collagen | Bone marrow | Monoclonal antibodies | Zoledronic acid | Lesions | Bone imaging
Journal Article
Osteoporosis International, ISSN 0937-941X, 7/2012, Volume 23, Issue 7, pp. 2043 - 2051
The ROSE study compared annual infusion with zoledronic acid and weekly generic alendronate. No significant differences in quality of life or health status... 
Adherence | Health status | Medicine & Public Health | Gynecology | Orthopedics | Rheumatology | Zoledronic acid | Generic alendronate | Endocrinology | Quality of life | Generic alendronate status | Health | MANAGEMENT | FRACTURE RATES | PERSISTENCE | ONCE-MONTHLY IBANDRONATE | OSTEOPOROSIS | BISPHOSPHONATES | THERAPY | WEEKLY ORAL ALENDRONATE | ENDOCRINOLOGY & METABOLISM | PREFERENCE | Humans | Middle Aged | Imidazoles - administration & dosage | Alendronate - therapeutic use | Activities of Daily Living | Osteoporosis, Postmenopausal - rehabilitation | Aged, 80 and over | Diphosphonates - therapeutic use | Female | Imidazoles - therapeutic use | Drug Administration Schedule | Administration, Oral | Bone Density Conservation Agents - therapeutic use | Psychometrics | Diphosphonates - administration & dosage | Patient Preference | Bone Density Conservation Agents - administration & dosage | Osteoporosis, Postmenopausal - drug therapy | Medication Adherence | Quality of Life | Aged | Infusions, Intravenous | Health Status | Alendronate - administration & dosage | Drugs, Generic | Osteoporosis | Complications and side effects | Dosage and administration | Alendronate | Analysis | Bones | Drug therapy | Preferences | Menopause | Alendronic acid | Inventories | Bone mass | Fractures | Personnel | Bisphosphonates | Post-menopause
Journal Article
Bone, ISSN 8756-3282, 2011, Volume 49, Issue 6, pp. 1331 - 1339
Journal Article
Journal of Tissue Engineering and Regenerative Medicine, ISSN 1932-6254, 09/2017, Volume 11, Issue 9, pp. 2603 - 2612
Alendronate (ALN) is known as an anti‐resorptive drug for the treatment of osteoporosis. Recently, ALN was found to stimulate osteogenic differentiation in... 
alendronate (ALN) | controlled release | osteogenesis | femoral defect | bone graft substitute | poly‐lactic‐co‐glycolic acid (PLGA) | poly-lactic-co-glycolic acid (PLGA) | ENGINEERING, BIOMEDICAL | RATS | OSTEOGENIC DIFFERENTIATION | PROLIFERATION | RELEASE | CELL & TISSUE ENGINEERING | CELL BIOLOGY | IN-VITRO | BISPHOSPHONATES | CO-GLYCOLIC ACID | POLY(D,L-LACTIDE-CO-GLYCOLIDE) NANOPARTICLES | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | EXPRESSION | MARROW STROMAL CELLS | Diaphyses - injuries | Femur - pathology | Polyglycolic Acid - pharmacology | Delayed-Action Preparations - chemistry | Male | Femur - diagnostic imaging | X-Ray Microtomography | Alendronate - chemistry | Lactic Acid - pharmacokinetics | Delayed-Action Preparations - pharmacology | Delayed-Action Preparations - pharmacokinetics | Alendronate - pharmacokinetics | Lactic Acid - pharmacology | Diaphyses - pathology | Femur - injuries | Lactic Acid - chemistry | Diaphyses - diagnostic imaging | Femur - metabolism | Osteogenesis - drug effects | Rats | Diaphyses - metabolism | Rats, Sprague-Dawley | Animals | Polyglycolic Acid - pharmacokinetics | Polyglycolic Acid - chemistry | Alendronate - pharmacology | Aluminum compounds | Osteoporosis | Bone morphogenetic proteins | Collagen | Analysis | Stem cells | Bone grafts | Femur | Mesenchyme | Stem cell transplantation | Bone (trabecular) | Bisphosphonates | Grafting | Diaphysis | Defects | Polylactide-co-glycolide | Microspheres | Alendronic acid | Bone growth | Biomedical materials | Allografts | Computed tomography | Ultrastructure | Rodents | Glycolic acid | Bones | Biocompatibility | Stiffness | Bone matrix | Repair | Controlled release | Bone morphogenetic protein 2 | Mechanical properties | Crosslinking | Bone healing | Group dynamics | Biomechanics | In vivo methods and tests | Bone | Differentiation | In vitro methods and tests | Energy absorption | Osteogenesis
Journal Article
Journal Article
by Liu, P and Sun, L and Zhou, DS and Zhang, P and Wang, YH and Li, D and Li, QH and Feng, RJ
SCIENTIFIC REPORTS, ISSN 2045-2322, 12/2015, Volume 5, Issue 1, p. 17387
Journal Article
Clinical Oral Investigations, ISSN 1432-6981, 9/2018, Volume 22, Issue 7, pp. 2527 - 2534
Journal Article
Scientific Reports, ISSN 2045-2322, 11/2016, Volume 6, Issue 1, p. 36707
We engineered nanomedicine with the stealth corona made up of densely packed bone seeking ligand, alendronic acid. In a typical nanoconstruct, alendronic acid... 
ANTI-PEG ANTIBODIES | POLYMERIC NANOPARTICLES | METASTASIS | BISPHOSPHONATE | DRUG-DELIVERY | POLY(ETHYLENE GLYCOL) | MULTIDISCIPLINARY SCIENCES | BONE MICROENVIRONMENT | AGENTS | CANCER | DISPOSITION | Crystals | Melanoma | Hydroxyapatite | Phospholipids | Hydrophobicity | Doxorubicin | Nanoparticles | Alendronic acid | Bone cancer | Acids | Osteosarcoma | Zeta potential | Internalization | Glycolic acid | Skeleton | Nanotechnology
Journal Article
Journal of Bone and Mineral Metabolism, ISSN 0914-8779, 11/2019, Volume 37, Issue 6, pp. 996 - 1003
Thalassemia, as the most prevalent genetic blood disorder, has many associated comorbidities including low bone mass. We studied the comparative effectiveness... 
Medicine & Public Health | Alendronate | Orthopedics | Metabolic Diseases | Zoledronic acid | Beta-thalassemia | Bone density | DNA nucleotidylexotransferase | Body mass index | Alendronic acid | Bone mass | Physical activity | Spine (lumbar) | Thalassemia | Hormone replacement therapy | Bone mineral density | Patients | Bisphosphonates
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2017, Volume 40, Issue 1, pp. 25 - 33
Journal Article
Osteoporosis International, ISSN 0937-941X, 04/2019, Volume 30, Issue 4, pp. 817 - 828
Journal Article
16.